A recent study provides the final long-term efficacy and safety results from the phase 3 ABILITY-1 trial’s open-label extension in patients with nonradiographic axial spondyloarthritis, which show that the anti–tumor necrosis factor agent adalimumab (Humira) provided sustained clinical and functional improvements through 3 years.
Anti—tumor necrosis factor (anti-TNF) agents have proven efficacy in treating patients with axial spondyloarthritis, including those patients with nonradiographic axial spondyloarthritis (nrAxSpA). A recent study provides the final long-term efficacy and safety results from the phase 3 ABILITY-1 trial’s open-label extension in patients with nrAxSpA, which show that the anti-TNF agent adalimumab (Humira) provided sustained clinical and functional improvements through 3 years.
Patients included in the extension were 18 years or older, had nrAxSpA, and had not responded adequately to (or had a contraindication for) at least 1 non-steroidal anti-inflammatory drug. The ABILITY-1 trial randomized patients to receive subcutaneous injections of either 40 mg of adalimumab or placebo every other week for 12 weeks, and in the open-label extension, patients received 40 mg of adalimumab every other week for up to 3 years. Patients in the total efficacy population (n = 185) were divided into a population of those positive for magnetic resonance imaging (MRI)—detected inflammation and for elevated C-reactive protein (CRP) levels (n = 142) and those who tested negative for both (n = 43).
Clinical and MRI remission were defined, respectively, as an Ankylosing Spondylitis Disease Activity Score (ASDAS) of less than 1.3 and a Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score of less than 2 for sacroiliac joints, spine, or both. Physical function was assessed using the Bath Ankylosing Spondylitis Functional Index (BASDAI).
The researchers found the following:
During the study period, there were no incidents of malignancy, vasculitis, demyelinating disease, or reactivation of hepatitis B reported, though serious adverse events, including infections, were reported by 17.4% of patients in the overall safety population.
The authors conclude that adalimumab provided sustained clinical and functional improvements through 3 years, and also provided suppression of MRI axial inflammation in patients with nrAxSpA. These findings, say the authors, support the favorable benefit-risk profile of long-term adalimumab therapy in this patient population.
Reference
van der Heijde D, Sieper J, Maksymowych WP, et al. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Res Ther. 2018;20(1):61. doi: 10.1186/s13075-018-1556-5.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.